Board of Directors
Our Board of Directors
Guided by a dynamic and highly experienced team with world-class credentials in the field of life sciences.
Chair of the Board of Directors, Chair of Remuneration Committee, Member of Audit Committee
From 2007 to end 2010, Martin served as President and Chief Executive Officer of Biovitrum AB and Sobi AB. From 1999 to 2007 he held various Executive Vice President positions at AstraZeneca Plc. and was a member of the Senior Executive Committee. He has held and holds various chairman and board member positions in biotech and biopharma companies. Currently he serves as Chairman of Zealand Pharma AS and is a board member of Basilea Pharmaceutica Ltd. Martin is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from Uppsala University.
Board Member, Member of Remuneration Committee
Harald serves as Chief Executive Officer, president and partner of the Datum Group, an investment company based in Oslo, Norway, a position he has held for over 25 years. Datum Group is controlled by Jan Haudemann-Andersen, the largest shareholder of Nykode. Harald holds several board positions in both listed and non-listed companies. In addition, he has held management positions at former Samuel Montague & Co., HSBC, and Handelsbanken, where he served as General Manager, Banking and led the Corporate Finance department in Norway. Mr. Arnet holds a BSBA from the University of Denver, USA, and has completed executive management courses at the London Business School.
Bernd R. Seizinger
Board Member, Member of R&D Committee
Bernd R. Seizinger, M.D., Ph.D., serves as chair or board member of several public and private biotech companies in the U.S., Europe, including Aprea, Aptose, BioInvent, CryptoMedix, Oncolytics and Oxford BioTherapeutics. In addition, he serves on the advisory board of Pureos BioVentures (Zurich) and is senior advisor to Hadean Ventures (Stockholm and Oslo). His previous roles include CEO and Senior Executive positions at GPC Biotech, Genome Therapeutics Corporation and Bristol-Myers Squibb. Before entering the biotech and pharma industries, he was a Senior Faculty Member of Harvard Medical School/Massachusetts General Hospital and Princeton University. He is a medical doctor and holds a Ph.D. in neurobiology.
Board Member, Chair of R&D Committee
Elaine has over 25 years of international experience working in the pharmaceutical industry and was a member of the senior R&D management teams in Eli Lilly and AstraZeneca. She has developed new molecules in therapy areas including virology, cancer, ophthalmology, respiratory and inflammation. Other former positions include co-founder and CEO of Carrick Therapeutics which developed a novel oncology pipeline rapidly transitioning from a preclinical start-up to a clinical stage oncology company. She sits on several international boards for companies in the biotech, services and adjacent areas including Evotec AG. Elaine holds a Ph.D. in Molecular Virology from the University of Edinburgh, Scotland.
Board Member, Chair of Audit Committee, Member of Remuneration Committee
Anders is Chief Investment Officer of the life science investment company Radforsk, which is focused on immunotherapies and precision medicines. He is an experienced investment and business development professional in the life science industry. His roles and responsibilities cover management positions, strategy and business development, research collaborations, licensing deals, M&A and IPOs. Anders also holds several chairman and non-executive director positions with Norwegian biotech companies. He has an MBE degree.
Board Member, Member of R&D Committee
Birgitte currently serves as Senior Vice President, Head of Clinical Development and Medical Affairs of Ascendis Pharma A/S (Nasdaq: ASNO) and as a non-executive director of Soleno Therapeutics Inc. (Nasdaq: SLNO). Previous senior positions in big pharma and biotech include: President, Head of R&D, Avrobio Inc; Head of R&D in Rare Diseases for GlaxoSmithKline; and CMO and SVP of Development at Swedish Orphan Biovitrum AB (Sobi). Her career also includes previous non-executive director positions at Ascendis Pharma, Wilson Therapeutics, TFS International as well as various positions at Amgen Inc., including Executive Development Director of Bone, Neuroscience & Inflammation. Birgitte received her M.D. and Ph.D. degrees from the University of Copenhagen, Denmark.
Board Member, Member of Remuneration Committee, Member of R&D Committee
Anne is an experienced executive with 30 years of experience in the life sciences industry, spanning large pharmaceutical, biotech, and specialty pharmaceutical companies. Her extensive leadership background includes CEO roles at three clinical-stage biotech businesses: Aerami Therapeutics, Synta Pharmaceuticals and Novoclem Therapeutics. This is complemented by significant experience in larger pharma, notably at Bausch Health, Sanofi, and GSK. At GSK, she held senior commercial roles at both local US and global levels and was responsible for running Sanofi’s North American commercial and medical operations. Anne also serves as a non-executive director of several international companies. She holds a Bachelor of Science in Chemistry from the University of North Alabama, USA.
Board Member, Member of Audit Committee
Christian is a partner at Andenæsgruppen. His prior professional experience and past roles include M&A, business development, and equity research with Norsk Hydro, Aker RGI, Morgan Stanley and Merrill Lynch. He is a CFA charter holder, has an MBA from IMD, and holds a business degree (siviløkonom) from the Norwegian School of Economics and Business Administration. In addition, Christian completed the first two years of law school at the University of Oslo.
Einar J. Greve
Deputy Board Member
Einar works as a strategic advisor with Cipriano AS. He was previously a partner of Wikborg Rein & Co and a partner of Arctic Securities ASA. He has held and holds various positions as chairman and board member of both Norwegian and international listed and unlisted companies. He has a Master of Law degree (cand.jur.) from the University of Oslo.
Observer to the Board
Trygve is an Investment Director with RASMUSSENGRUPPEN AS, a major shareholder of the Company. Prior to joining RASMUSSENGRUPPEN AS, he worked as an equity analyst with DNB Markets and as product manager with ABB. He has held several Board positions with Norwegian companies. He holds a Ph.D. in Engineering Cybernetics from the Norwegian University of Science and Technology (NTNU).